{
    "nctId": "NCT03966898",
    "briefTitle": "A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer",
    "officialTitle": "A Phase III Study to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole Versus Placebo in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 426,
    "primaryOutcomeMeasure": "Investigator-assessed PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has the pathologically-confirmed diagnosis of locally recurrent or metastatic, hormone-receptor positive, HER2 negative Breast Cancer.\n2. Age: 18 - 75 years old\n3. No prior systemic anti-cancer therapy for advanced HR+ disease.\n4. Eastern Cooperative Oncology Group \\[ECOG\\] 0-1\n\nExclusion Criteria:\n\n1. Patients who received prior treatment with any CDK4/6 inhibitor.\n2. Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \\> 2), or ventricular arrhythmia which need medical intervention.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}